%0 Journal Article %A Kalliopi Zachou %A Pinelopi Arvaniti %A Aggeliki Lyberopoulou %A Eirini Sevdali %A Matthaios Speletas %A Maria Ioannou %A George K. Koukoulis %A Yves Renaudineau %A George N. Dalekos %T Altered DNA methylation pattern characterizes the peripheral immune cells of patients with autoimmune hepatitis %D 2021 %R 10.1101/2021.07.01.21259836 %J medRxiv %P 2021.07.01.21259836 %X Objective AIH is a chronic liver disease of unknown aetiology with favourable response to immunosuppression. Little is known about the impact of methylation modifications on disease pathogenesis.Design 10 patients with AIH at diagnosis (time-point 1; tp1), 9 with primary biliary cholangitis (PBC) and 10 healthy controls (HC) were investigated. 8/10 AIH patients were also investigated following biochemical remission (time-point 2; tp2). Peripheral CD19(+)- and CD4(+)-cells were isolated to study global DNA methylation (5mC)/hydroxymethylation (5hmC) by ELISA and mRNA of DNA methylation (DNMT1/3A/3B)/hydroxymethylation enzymes (TET1/2/3) by quantitative RT-PCR. Epigenome wide association study (EWAS) was performed in CD4(+)-cells (Illumina HumanMethylation 850K array) in AIH and HC. Differences in total 5mC/5hmC state between AIH-tp1 and HC were also assessed by immunohistochemistry (IHC) on paraffin embedded liver sections.Results Reduced TET1 and increased DNMT3A mRNA levels characterized CD19(+) and CD4(+) lymphocytes from AIH-tp1 patients compared to HC and PBC respectively, without affecting global DNA 5mC/5hmC. In AIH-tp1, CD4(+) DNMT3A expression was negatively correlated with serum IgG (p=0.03). In remission (AIH-tp2), DNMT3A decreased in both CD19(+) and CD4(+)-cells (p=0.02, p=0.03, respectively). EWAS in CD4(+)-cells from AIH patients confirmed important modifications in genes implicated in immune responses (HLA-DP, TNF, lnRNAs and CD86). IHC confirmed increased 5hmC staining of periportal infiltrating lymphocytes in AIH-tp1.Conclusion Altered expression of TET1 and DNMT3A, characterizes peripheral immune cells in AIH. DNMT3A is associated with disease activity and decreased following therapeutic response. Gene specific DNA methylation modifications affect immunologic pathways that may play an important role in AIH pathogenesis.Summary box What is already known?Autoimmune hepatitis (AIH) is a non-resolving chronic liver disease of unknown aetiology and favourable response to immunosuppression. Since the interplay between the genetic background and the environment seems to be fundamental for AIH pathogenesis, epigenetic modifications may be of particular importance.What are the new findings?We found characteristic alterations of DNA methylation in peripheral immune cells of AIH patients, which were associated with disease activity and modified by immunosuppressive treatment.How might it impact on clinical practice in the foreseeable future?These results provide the first evidence that epigenetics play a role in AIH pathogenesis, which may have therapeutic implications for the management of the disease.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementThis research project was supported in part by a research grant from the Hellenic Association for the Study of the Liver (HASL) and the Research Committee of the University of Thessaly (No. 2466). P. Arvaniti was also supported by a research grant for rare diseases by the Federation for the Development of Internal Medicine in Europe (FDIME).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients consented to participate in this study. The ethical committee of the General University Hospital of Larissa approved the protocol which conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee (21-03-2016/2258).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are included within the article.5hmC5-hydroxymethyl-cytosine5mC5-methyl-cytosineAIHAutoimmune hepatitisALTAlanine aminotransferaseAMAAntimitochondrial autoantibodiesANAAntinuclear autoantibodiesASTAspartate aminotransferaseDAVIDDatabase for Annotation, Visualization and Integrated DiscoveryDMPsDifferentially methylated probesDMRsDifferentially methylated regionsDNMTsDNA methyl-transferasesEWASEpigenome wide association studiesGAPDHGlyceraldehyde-3-Phosphate DehydrogenaseGWASGenome wide association studiesHCHealth controlsHLAHuman leucocyte antigenMHCMajor Histocompatibility complexmiRNAsmicro RNAsMMFMycophenolate mofetilNASHNon alcoholic steatohepatitisPBCPrimary biliary cholangitisPBMCsPeripheral blood mononuclear cellsSjSSjögren’s syndromeSLASoluble liver antigenSLESystemic lupus erythematosusSMASmooth muscle cell antibodiesTETsTen-eleven translocation deoxygenasesTSSTranscription start sitestp1time point 1tp2time point 2TregsT regulatoryTSSTranscription start siteUTRUntranslated region %U https://www.medrxiv.org/content/medrxiv/early/2021/07/05/2021.07.01.21259836.full.pdf